AstraZeneca and Eli Lilly are to plough straight ahead with the Phase III part of the AMARANTH study testing their oral beta secretase cleaving enzyme (BACE) inhibitor AZD3293 in early Alzheimer's after an encouraging interim safety review, building confidence in this potential disease-modifying drug class.
AMARANTH will continue into the Phase III of the Phase II/III seamless trial, the companies said after the independent data...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
